基于体细胞突变数据库筛选免疫原性结直肠癌高频新抗原的方法
收稿日期: 2020-04-10
修回日期: 2020-05-15
网络出版日期: 2020-05-19
基金资助
国家自然科学基金项目编号(81702826);深圳市科技创新委员会项目资助编号(JCYJ20170303151334808);深圳市科技创新委员会项目资助编号(JCYJ20170817150015170)
A method of screening highly common neoantigens with immunogenicity in colorectal cancer based on public somatic mutation library
Received date: 2020-04-10
Revised date: 2020-05-15
Online published: 2020-05-19
Supported by
Supported by the National Natural Science Foundation of China No(81702826);Science, Technology and Innovation Commission of Shenzhen Municipality Nos(JCYJ20170303151334808);Science, Technology and Innovation Commission of Shenzhen Municipality Nos(JCYJ20170817150015170)
结直肠癌是世界高发和高致死率的恶性肿瘤。靶向新抗原的免疫治疗已被证实可以诱导癌症患者肿瘤持续消退,但这些特异性新抗原,仅适用于个体精准治疗。随着大量的高频肿瘤基因突变被发现,这些与突变相关的高频新抗原可覆盖更多人群,具有较强的临床意义。然而目前结直肠癌中是否也存在高频新抗原仍不清楚。本研究利用来源于321个结直肠癌患者的体细胞突变数据库,联合1种标准过滤和7种预测算法,筛选并获得了25个基于中国人高频分型HLA-A*1101限制性的高频新抗原,它们均具有高亲和力(IC50<50 nmol/L)和高呈递分值(>0.90);其中,除了阳性对照多肽KRAS_G12V8-16外,11个高频新抗原能够在体外诱导细胞毒性T淋巴细胞(cytotoxic T lymphocyte, CTL)分泌γ干扰素(interferon gamma, IFN-γ),证实具有免疫原性。选取免疫原性最强的新抗原C1orf170_S418G413-421及阳性对照多肽KRAS_G12V8-16体外刺激T细胞,利用流式细胞分选及单细胞转录组测序技术,获得其特异性CTL的免疫组库信息,所构建的TCR-T（T-cell receptor engineered T cell）能够识别新抗原并分泌细胞因子。以上结果表明,本研究开发了一种利用体细胞数据库预测并体外筛选验证具有免疫原性高频新抗原的方法,为结直肠癌及其他癌种的多肽、DC（dendritic cells）疫苗、TCR-like抗体、TCR-T等免疫治疗提供了重要的多肽靶点和TCR信息,具有实际的临床应用价值。
秦丽丽, 李毅坚, 梁兆端, 陈蕾, 李文慧, 陈超, 黄亚灵, 张乐, 刘松明, 邱思, 葛玉萍, 彭文婷, 林欣欣, 张秀清, 董旋, 李波 . 基于体细胞突变数据库筛选免疫原性结直肠癌高频新抗原的方法[J]. 遗传, 2020 , 42(6) : 599 -612 . DOI: 10.16288/j.yczz.20-032
Colorectal cancer (CRC) is a malignant cancer with high incidence and mortality in the world. Immunotherapy targeting neoantigens can induce durable tumor regression in cancer patients, but is almost limited to personalized precision therapy, due to the individual differences of unique neoantigens. With the discovery of many common oncogenic mutations, and such mutation-associated neoantigens could cover more patients, and hence are valuable in clinical field. However, whether the common neoantigens can be identified in CRC is unknown. Combining the somatic mutations data from 321 CRC patients with a filter standard and 7 predicted algorithms, we screened and obtained 25 HLA-A*1101-restricted common neoantigens with a high binding affinity (IC50<50 nmol/L) and presentation score (>0.90). Besides the positive epitope KRAS_G12V8-16, 11 out of 25 common neoantigens specifically induced in vitro pre- stimulated cytotoxic lymphocyte (CTL) to secrete interferon gamma (IFN-γ). Moreover, combining cell-sorting technology and single-cell RNA sequencing, the immune repertoire profiles of C1orf170_S418G413-421 and KRAS_G12V8-16-specific CTL were analyzed and validated. Their related T-cell receptor engineered T cell (TCR-T) cells could also recognize the neoantigens and secrete IFN-γ. Hence, we have established a method to screen for common neoantigens with immunogenicity in CRC based on the public somatic mutation library. It can provide essential peptide and TCR information for immunotherapies, such as peptides, dendritic cells (DC) vaccines, TCR-like antibodies, TCR-T, etc., for the CRC and other cancers, which has practical application value in the clinics.
Key words： colorectal cancer; common; neoantigen; presentation
| [1] | Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018,68(6):394-424. |
| [2] | Magee MS, Kraft CL, Abraham TS, Baybutt TR, Marszalowicz GP, Li P, Waldman SA, Snook AE . GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. Oncoimmunology, 2016,5(10):e1227897. |
| [3] | Ciardiello D, Vitiello PP, Cardone C, Martini G, Troiani T, Martinelli E, Ciardiello F . Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. Cancer Treat Rev, 2019,76:22-32. |
| [4] | Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA . T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther, 2011,19(3):620-626. |
| [5] | Zhang CC, Wang Z, Yang Z, Wang ML, Li SQ, Li YY, Zhang R, Xiong ZX, Wei ZH, Shen JJ, Luo YL, Zhang QZ, Liu LM, Qin H, Liu W, Wu F, Chen W, Pan F, Zhang XQ, Bie P, Liang HJ, Pecher G, Qian C . Phase I escalating- dose trial of CAR-T therapy targeting CEA + metastatic colorectal cancers . Mol Ther, 2017,25(5):1248-1258. |
| [6] | Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA . Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther, 2010,18(4):843-851. |
| [7] | Zhou Z, Lyu XZ, Wu JC, Yang XY, Wu SS, Zhou J, Gu X, Su ZX, Chen SQ . TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection. R Soc Open Sci, 2017,4(4):170050. |
| [8] | Nonomura C, Otsuka M, Kondou R, Iizuka A, Miyata H, Ashizawa T, Sakura N, Yoshikawa S, Kiyohara Y, Ohshima K, Urakami K, Nagashima T, Ohnami S, Kusuhara M, Mitsuya K, Hayashi N, Nakasu Y, Mochizuki T, Yamaguchi K, Akiyama Y . Identification of a neoantigen epitope in a melanoma patient with good response to anti- PD-1 antibody therapy. Immunol Lett, 2019,208:52-59. |
| [9] | Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA . T-Cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med, 2016,375(23):2255-2262. |
| [10] | Wirth TC, Kühnel F . Neoantigen targeting-dawn of a new era in cancer immunotherapy? Front Immunol, 2017,8:1848. |
| [11] | Cafri G, Yossef R, Pasetto A, Deniger DC, Lu YC, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT, Jafferji M, Sachs A, Prickett T, Robbins PF, Rosenberg SA . Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nat Commun, 2019,10(1):449. |
| [12] | Nielsen M, Lundegaard C, Worning P, Lauem?ller SL, Lamberth K, Buus S, Brunak S, Lund O . Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci, 2003,12(5):1007-1017. |
| [13] | Nielsen M, Andreatta M . NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med, 2016,8(1):33. |
| [14] | Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M . NetMHCpan-4.0: improved Peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol, 2017,199(9):3360-3368. |
| [15] | Liu G, Li DL, Li Z, Qiu S, Li WH, Chao CC, Yang NB, Li HD, Cheng Z, Song X, Cheng L, Zhang XQ, Wang J, Yang HM, Ma K, Hou Y, Li B . PSSMHCpan: a novel PSSM-based software for predicting class I peptide-HLA binding affinity. Gigascience, 2017,6(5):1-11. |
| [16] | Zhang H, Lund O, Nielsen M . The PickPocket method for predicting binding specificities for receptors based on receptor pocket similarities: application to MHC-peptide binding. Bioinformatics, 2009,25(10):1293-1299. |
| [17] | Peters B, Sette A . Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics, 2005,6:132. |
| [18] | Creaney J, Ma S, Sneddon SA, Tourigny MR, Dick IM, Leon JS, Khong A, Fisher SA, Lake RA, Lesterhuis WJ, Nowak AK, Leary S, Watson MW, Robinson BW . Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen. Oncoimmunology, 2015,4(7):e1011492. |
| [19] | Hu WP, Li YP, Zhang XQ . MHC-I epitope presentation prediction based on transfer learning.Hereditas(Beijing), 41(11):1041-1049. |
| [19] | 胡伟澎, 李佑平, 张秀清 . 基于迁移学习的MHC-I型抗原表位呈递预测. 遗传, 41(11):1041-1049. |
| [20] | Hu WP, Qiu S, Li YP, Lin XX, Zhang L, Xiang HT, Han X, Chen L, Li S, Li WH, Ren Z, Hou GX, Lin ZL, Lu JL, Liu G, Li B, Lee LJ . EPIP: MHC-I epitope prediction integrating mass spectrometry derived motifs and tissue- specific expression profile. bioRxiv, 2019,567081. |
| [21] | Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med, 2018, 10(436): eaao5931. |
| [22] | Yamamiya D, Mizukoshi E, Kaji K, Terashima T, Kitahara M, Yamashita T, Arai K, Fushimi K, Honda M, Kaneko S . Immune responses of human T lymphocytes to novel hepatitis B virus-derived peptides. PLoS One, 2018,13(6):e0198264. |
| [23] | Rodenko B, Toebes M, Hadrup SR, van Esch WJ, Molenaar AM, Schumacher TN, Ovaa H,. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc, 2006,1(3):1120-1132. |
| [24] | Kim MS, Ma JS, Yun HY, Cao Y, Kim JY, Chi V, Wang D, Woods A, Sherwood L, Caballero D, Gonzalez J, Schultz PG, Young TS, Kim CH . Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J Am Chem Soc, 2015,137(8):2832-2835. |
| [25] | Ali M, Foldvari Z, Giannakopoulou E, B?schen ML, Str?nen E, Yang W, Toebes M, Schubert B, Kohlbacher O, Schumacher TN, Olweus J . Induction of neoantigen- reactive T cells from healthy donors. Nat Protoc, 2019,14(6):1926-1943. |
| [26] | Lancaster EM, Jablons D, Kratz JR . Applications of next-generation sequencing in eoantigen prediction and cancer vaccine development. Genet Test Mol Biomarkers, 2019,24(2):59-66. |
| [27] | The problem with neoantigen prediction. Nat Biotechnol, 2017,35(2):97. |
| [28] | Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS, Li YF, El-Gamil M, Rosenberg SA, Robbins PF, . Isolation of neoantigen- specific T cells from tumor and peripheral lymphocytes. J Clin Invest, 2015,125(10):3981-3991. |
| [29] | Lin QY, Liu Z, Luo MJ, Zheng H, Qiao S, Han CL, Deng DQ, Fan Z, Lu YF, Zhang ZH, Luo QM . Visualizing DC morphology and T cell motility to characterize DC-T cell encounters in mouse lymph nodes under mTOR inhibition. Sci China Life Sci, 2019,62(9):1168-1177. |
| [30] | Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW, Yeong JPS, Nahar R, Zhang T, Kared H, Duan K, Ang N, Poidinger M, Lee YY, Larbi A, Khng AJ, Tan E, Fu C, Mathew R, Teo M, Lim WT, Toh CK, Ong BH, Koh T, Hillmer AM, Takano A, Lim TKH, Tan EH, Zhai W, Tan DSW, Tan IB, Newell EW . Bystander CD8 + T cells are abundant and phenotypically distinct in human tumour infiltrates . Nature, 2018,557(7706):575-579. |
| [31] | Whiteside SK, Snook JP, Williams MA, Weis JJ . Bystander T Cells: a balancing act of friends and foes. Trends Immunol, 2018,39(12):1021-1035. |
| [32] | Kim TS, Shin EC . The activation of bystander CD8 + T cells and their roles in viral infection . Exp Mol Med, 2019,51(12):1-9. |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:
